Recent reports suggest that resistance to anti-cancer tyrosine kinase inhibitors is frequently triggered by the presence of additional receptor tyrosine kinase ligands [31], and in vitro experiments suggest that ligand-driven activation of alternative receptors in the HER family may present a recurrent mechanism of resistance in breast cancer cells [32]. The gene discussed is NTRK1; the disease is breast carcinoma.